| 17806152 |
Savarino L, Fioravanti A, Leo G, Aloisi R, Mian M: Anthraquinone-2,6-disulfonic acid as a disease-modifying osteoarthritis drug: an in vitro and in vivo study. Clin Orthop Relat Res. 2007 Aug;461:231-7.
The evidence for disease-modifying activity of anthraquinone-2,6-disulfonic acid was (1) the in vitro dose-dependent inhibition of cathepsin B activity, (2) the in vitro time- and dose-dependent inhibition of interleukin-1beta-stimulated proteoglycan release from the cartilage matrix, and (3) the in vivo reduction of all cartilage degeneration parameters. |
112(1,2,2,2) |
Details |
| 18789614 |
Wang C, Jiang Z, Yao J, Wu X, Sun L, Liu C, Duan W, Yan M, Sun L, Liu J, Zhang L: Participation of cathepsin B in emodin-induced apoptosis in HK-2 Cells. Toxicol Lett. 2008 Oct 1;181(3):196-204. Epub 2008 Sep 11.
Emodin (1,3,8-trihydroxy-6-methyl-anthraquinone) and rhein (4,5-dihydroxyanthraquinone-2-carboxyl acid) are two main active compounds in total rhubarb anthraquinones (TRAs), which showed nephrotoxicity in Sprague Dawley (S.D.) rats in our previous study. |
2(0,0,0,2) |
Details |